Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

van Royen, N; Schirmer, SH; Atasever, B; Behrens, CY; Ubbink, D; Buschmann, EE; Voskuil, M; Bot, P; Hoefer, I; Schlingemann, RO; Biemond, BJ; Tijssen, JG; Bode, C; Schaper, W; Oskam, J; Legemate, DA; Piek, JJ; Buschmann, I.
START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
Circulation. 2005; 112(7): 1040-1046.
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Buschmann Eva Elina

Dimensions Citations:

Plum Analytics:
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was recently shown to increase collateral flow index in patients with coronary artery disease. Experimental models showed beneficial effects of GM-CSF on collateral artery growth in the peripheral circulation. Thus, in the present study, we evaluated the effects of GM-CSF in patients with peripheral artery disease. A double-blinded, randomized, placebo-controlled study was performed in 40 patients with moderate or severe intermittent claudication. Patients were treated with placebo or subcutaneously applied GM-CSF (10 microg/kg) for a period of 14 days (total of 7 injections). GM-CSF treatment led to a strong increase in total white blood cell count and C-reactive protein. Monocyte fraction initially increased but thereafter decreased significantly as compared with baseline. Both the placebo group and the treatment group showed a significant increase in walking distance at day 14 (placebo: 127+/-67 versus 184+/-87 meters, P=0.03, GM-CSF: 126+/-66 versus 189+/-141 meters, P=0.04) and at day 90. Change in walking time, the primary end point of the study, was not different between groups. No change in ankle-brachial index was found on GM-CSF treatment at day 14 or at day 90. Laser Doppler flowmetry measurements showed a significant decrease in microcirculatory flow reserve in the control group (P=0.03) and no change in the GM-CSF group. The present study does not support the use of GM-CSF for treatment of patients with moderate or severe intermittent claudication. Issues that need to be addressed are dosing, the selection of patients, and potential differences between GM-CSF effects in the coronary and the peripheral circulation.
Find related publications in this database (using NLM MeSH Indexing)
Angioplasty, Balloon -
Arterial Occlusive Diseases - drug therapy
Arterial Occlusive Diseases - surgery
Arterial Occlusive Diseases - therapy
Arteries - drug effects
Blood Flow Velocity - drug effects
Brachial Artery - drug effects
Brachial Artery - pathology
Coronary Artery Bypass -
Exercise Test -
Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Humans -
Injections, Subcutaneous -
Pilot Projects -
Placebos -
Recombinant Proteins -
Skin - blood supply
Walking - physiology

Find related publications in this database (Keywords)
collateral circulation
growth substances
peripheral vascular disease
© Meduni Graz Impressum